Drugs / BEY2153
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04476303 | Aug 2020 → Nov 2021 | Alzheimer disease | BeyondBio Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06885567 | Jul 2025 → Jul 2028 expected | Alzheimer disease | BeyondBio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEY2153 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04476303 ↗ |
| Route | Oral | “After Oral Administration” NCT04476303 ↗ |